BBCMF (Lir Life Sciences) 12-1 Month Momentum %: N/A% (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BBCMF Lir Life Sciences Corp BBCMF
15 GF Score
Price $0.05
View Full Analysis

What is Lir Life Sciences 12-1 Month Momentum %?

Lir Life Sciences BBCMF 15 12-1 Month Momentum % is N/A% as of Jul. 19, 2026. GuruFocus rates BBCMF with a GF Score™ of 15/100. Among 1,356 Biotechnology companies, Lir Life Sciences ranks worse than 73746.24% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-19), Lir Life Sciences's 12-1 Month Momentum % is N/A%.

The industry rank for Lir Life Sciences's 12-1 Month Momentum % or its related term are showing as below:

BBCMF's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -15.66
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Lir Life Sciences  (OTCPK:BBCMF) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Lir Life Sciences 12-1 Month Momentum % Related Terms

BBCMF
15GF Score
Lir Life Sciences Corp BBCMF
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lir Life Sciences  (OTCPK:BBCMF) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of N/A% mean?
Lir Life Sciences (BBCMF) has a 12-1 Month Momentum % of N/A% as of Jul. 19, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Lir Life Sciences and its competitors. According to the industry distribution chart, Lir Life Sciences ranks #999999 out of 1356 companies in the Biotechnology industry.
Is Lir Life Sciences' 12-1 Month Momentum % too high?
Lir Life Sciences' current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Lir Life Sciences ranks #999999 out of 1356 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #999999 out of 1356 companies for 12-1 Month Momentum %. This places Lir Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Lir Life Sciences and its competitors. Lir Life Sciences's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current 12-1 Month Momentum % is N/A% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lir Life Sciences Business Description

Other Exchanges N790:GermanySKNY:Canada
Address 505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score

Get the complete analysis for BBCMF

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.05
Price